Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.350 +0.100 (+8.00%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,901,670
Open	1.360
Bid (Size)	1.350 (800)
Ask (Size)	1.360 (100)
Prev. Close	1.250
Today's Range	1.250 - 1.390
52wk Range	0.2400 - 3.830
Shares Outstanding	88,268,078
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

May 21, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 14, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-8.2%	-8.2%
1 Month	+5.5%	+5.5%
3 Month	+32.4%	+32.4%
6 Month	-16.1%	-16.1%
1 Year	+325.9%	+325.9%

More News

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

May 07, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

What's going on in today's after hours session ↗

April 20, 2026

Via Chartmill

Cognition Therapeutics (NASDAQ:CGTX) Narrows Loss, Eyes Key FDA Meeting on DLB Drug ↗

March 26, 2026

Via Chartmill

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

April 07, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics CEO Issues Letter to Shareholders

March 31, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

March 26, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

March 23, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

March 17, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

March 02, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

February 05, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

January 27, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

January 06, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

December 03, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 01, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

November 13, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

November 06, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Here are the top movers in Monday's session. ↗

September 15, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 15, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

September 15, 2025

Via Chartmill

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 ↗

September 03, 2025

Via The Motley Fool

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

September 02, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Wondering what's happening in today's pre-market session? ↗

August 28, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 28, 2025

Via Benzinga

Frequently Asked Questions

Is Cognition Therapeutics, Inc. - Common Stock publicly traded?

Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?

Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?

The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market

What is the current price of Cognition Therapeutics, Inc. - Common Stock?

The current price of Cognition Therapeutics, Inc. - Common Stock is 1.350

When was Cognition Therapeutics, Inc. - Common Stock last traded?

The last trade of Cognition Therapeutics, Inc. - Common Stock was at 06/02/26 04:00 PM ET

What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?

The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 119.16M

How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?

Cognition Therapeutics, Inc. - Common Stock has 119M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.